Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer
View abstract on PubMed
Summary
This summary is machine-generated.The V600E BRAF mutation is linked to worse survival and higher recurrence rates in patients undergoing colorectal liver metastasis resection. This mutation is a stronger prognostic factor than KRAS mutations, identifying it as the primary determinant of outcomes in this patient group.
Area Of Science
- Oncology
- Genetics
- Surgical Oncology
Background
- BRAF mutations are associated with aggressive tumor biology in colorectal cancer.
- The prognostic impact of specific BRAF mutations (V600E and non-V600E) on survival and recurrence after colorectal liver metastasis (CRLM) resection is not well-established.
Purpose Of The Study
- To investigate the prognostic significance of BRAF mutations (V600E and non-V600E) in patients with CRLM.
- To compare the prognostic value of BRAF mutations against other determinants like KRAS mutations.
Main Methods
- Retrospective cohort study of 849 patients who underwent curative-intent hepatectomy for CRLM between 2000 and 2016.
- Analysis of BRAF and KRAS mutational status.
- Multivariate Cox proportional hazards regression models were used to assess overall survival (OS) and disease-free survival (DFS).
Main Results
- The V600E BRAF mutation was significantly associated with worse OS (HR, 2.76) and DFS (HR, 2.04) compared to wild-type BRAF/KRAS.
- Non-V600E BRAF mutations did not show a significant association with survival outcomes.
- The V600E BRAF mutation demonstrated a stronger prognostic association with OS and DFS than KRAS mutations.
Conclusions
- The V600E BRAF mutation is a significant predictor of poor prognosis and increased recurrence risk in patients with resected CRLM.
- V600E BRAF mutation is a stronger prognostic factor than KRAS mutations and the most potent determinant of outcomes in the overall cohort.